DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

HER2 low and ultralow may have less relevance in the future as studies with T-DXd and similar agents are ongoing to assess activity in true HER2 0 cases, said Mayer.

More information: Marcus Schmidt et al, HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity, Oncotarget (2024). DOI: 10.18632/oncotarget.28598.

BUFFALO, NY - January 22, 2025 – A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled “Evolving concepts in HER2-low breast cancer: Genomic insights, definitions ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

AI could help pathologists identify HER2-low and HER2-ultralow breast cancers with greater accuracy, according to findings scheduled for presentation at ASCO Annual Meeting.In a study of more than ...

In the HER2-low population, findings showed treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy (hazard ratio, ...

Prior to the approval of ENHERTU following chemotherapy in HER2 low metastatic breast cancer based on the DESTINY-Breast04 trial, there were no targeted therapies approved specifically for ...

Use of AI assistance reduced the misclassification of HER2-low and HER2-ultralow breast cancers as HER2-null by 24%, said study presenter Marina De Brot, MD, PhD, of AC Camargo Cancer Center in ...

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as a desire for more sensitive assays that may better quantify ...